{
    "clinical_study": {
        "@rank": "24874", 
        "arm_group": [
            {
                "arm_group_label": "orteronel 200mg/300mg", 
                "arm_group_type": "Experimental", 
                "description": "orteronel + Prednisone"
            }, 
            {
                "arm_group_label": "orteronel 200mg/400mg", 
                "arm_group_type": "Experimental", 
                "description": "orteronel + Prednisone"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Placebo + Prednisone"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind, placebo-controlled, multiregional Phase1/2 study to characterize the\n      pharmacokinetic and pharmacodynamic responses to orteronel when administered concomitantly\n      with prednisone in Chemotherapy-Na\u00efve Patients With Castration-Resistant Prostate Cancer"
        }, 
        "brief_title": "Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Na\u00efve Patients With Castration-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients 18 years or older\n\n          -  Voluntary written consent must be given before performance of any study-related\n             procedure not part of standard medical care, with the understanding that consent may\n             be withdrawn by the patient at any time without prejudice to future medical care\n\n          -  Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma\n\n          -  Prior surgical castration or concurrent use of an agent for medical castration (e.g.\n             GnRH analogue)\n\n          -  PSA \u2265 2 ng/mL at screening\n\n          -  Progressive disease based on PSA and/or radiographic criteria\n\n        Exclusion Criteria:\n\n          -  Prior therapy with orteronel, ketoconazole, aminoglutethimide, or abiraterone.\n\n          -  Known hypersensitivity to compounds related to orteronel, orteronel excipients,\n             prednisone (or commercially available equivalent), or GnRH analogue.\n\n          -  All antiandrogen therapy (including bicalutamide) is excluded within 4 weeks before\n             the first dose of study drug. Any other therapies for prostate cancer, other than\n             GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins\n             (megesterol), or 5- alpha reductase inhibitors (eg, finasteride or dutasteride), must\n             be discontinued 2 weeks before the first dose of study drug.\n\n          -  Continuous daily use of oral prednisone (or commercially available equivalent), oral\n             dexamethasone, or other systemic corticosteroids for more than 2 weeks within the 3\n             months before screening (inhaled, nasal, and local steroids [eg, joint injection] are\n             allowed).\n\n          -  Prior chemotherapy for prostate cancer, with the exception of neoadjuvant/adjuvant\n             therapy as part of initial primary treatment for local disease that was completed 2\n             or more years before screening.\n\n        Please note that there are additional inclusion and exclusion criteria. The study center\n        will determine if you meet all of the criteria.\n\n        Site personnel will explain the trial in detail and answer any question you may have if\n        you do qualify for the study. You can then decide whether or not you wish to participate.\n        If you do not qualify for the trial, site personnel will explain the reasons"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "137", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666314", 
            "org_study_id": "C21013", 
            "secondary_id": "2012-001539-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "orteronel 200mg/300mg", 
                "description": "Patients will be randomized to receive orteronel 200 mg BID or orteronel 300 mg BID\nStudy drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg BID continuously throughout the study.", 
                "intervention_name": "orteronel 200mg/300mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "orteronel 200mg/400mg", 
                "description": "Patients will be randomized to receive orteronel 200 mg BID or orteronel 400 mg BID.\nStudy drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg BID continuously throughout the study.", 
                "intervention_name": "orteronel 200mg/400mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients will be randomized to receive placebo (Cycle 1 only).\nStudy drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg BID continuously throughout the study.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "castrate resistant prostate cancer,", 
            "CRPC,", 
            "orteronel,", 
            "TAK-700"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68130"
                }, 
                "name": "Urology Cancer Center, PC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Na\u00efve Patients With Castration-Resistant Prostate Cancer", 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with serum testosterone levels reduced to \u2264 2 ng/dL", 
            "safety_issue": "No", 
            "time_frame": "Serum testosterone level in patients at screening; Cycle 1-Day 1, 8, 15, and 22; Cycle 2, 3, 4, and 5 - Day 1. Each cycle is a 28-day cycle (upto 140 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666314"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with serum testosterone levels reduced to \u2264 2 ng/dL", 
                "safety_issue": "No", 
                "time_frame": "Serum testosterone level in patients at screening; Cycle 1-Day 1, 8, 15, and 22; Cycle 2, 3, 4, and 5 - Day 1. Each cycle is a 28-day cycle (upto 140 days)"
            }, 
            {
                "measure": "Serum testosterone level", 
                "safety_issue": "No", 
                "time_frame": "Change in the serum testosterone level at screening; Cycle 1-Day 1, 8, 15, and 22; Cycle 2, 3, 4, and 5 - Day 1. Each cycle is a 28-day cycle (upto 140 days)"
            }, 
            {
                "measure": "PSA reduction \u2265 50%", 
                "safety_issue": "No", 
                "time_frame": "At screening, Cycle 1, 2, 3, 4 and 5- Day 1. Each cycle is a 28-day cycle."
            }, 
            {
                "measure": "Pharmacodynamic effects of orteronel measured by endocrine markers plotted over time", 
                "safety_issue": "No", 
                "time_frame": "At screening; Cycle 1-Day 1, 8, 15, and 22; Cycle 2, 3, 4, and 5 - Day 1. Each cycle is a 28-day cycle"
            }, 
            {
                "measure": "PK parameters for orteronel, including, but not limited to, Cmax, Area under Curve (AUC),Tmax, and the cumulative amount of unchanged drug excreted into the urine (Ae) in all treatment groups", 
                "safety_issue": "No", 
                "time_frame": "Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose"
            }, 
            {
                "measure": "Number of adverse events (AEs), serious adverse events (SAEs), assessments of clinical laboratory values, vital sign measurements, physical examination findings, and electrocardiograms (ECGs) in all treatment groups", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of the informed consent form through 30 days after the last dose of study drug, approximately 2.5 years"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}